# The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Study · id `cardio:ct-nct06058585` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06058585](<https://clinicaltrials.gov/study/NCT06058585>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06058585

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

## Technical summary

Registry record NCT06058585. Randomized; quadruple masking; primary purpose treatment. Start 2024-09-04 (actual); primary completion 2029-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2000 participants (planned count; ClinicalTrials.gov record NCT06058585, source copy `cardio:ctgov-nct06058585-2026-10-05`, retrieved 2026-10-26)
- Started: 2024-09-04 (actual) (ClinicalTrials.gov record NCT06058585, source copy `cardio:ctgov-nct06058585-2026-10-05`, retrieved 2026-10-26)
- Primary completion: 2029-12-31 (anticipated) (ClinicalTrials.gov record NCT06058585, source copy `cardio:ctgov-nct06058585-2026-10-05`, retrieved 2026-10-26)
- Completion: 2029-12-31 (anticipated) (ClinicalTrials.gov record NCT06058585, source copy `cardio:ctgov-nct06058585-2026-10-05`, retrieved 2026-10-26)
- Countries: Australia; India; New Zealand; Spain; Sri Lanka (ClinicalTrials.gov record NCT06058585, source copy `cardio:ctgov-nct06058585-2026-10-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06058585-2026-10-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
- Acronym: CAPTIVATE
- Condition: Chronic Kidney Diseases
- Intervention (Drug): Finerenone
- Intervention (Drug): Placebo Finerenone
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo semaglutide
- Lead sponsor: The George Institute
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Finerenone (`cardio:finerenone`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: The George Institute for Global Health (`core:george-institute`)

## Provenance

Content hash: f4d9afeedfce79e35b5044cc765c26c82950a1aa75a652d370074ed5310d629e
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
